Navigation Links
Visionary Pharmaceuticals, Inc., Announces Initial Seed Round Investments and the Launch of TH17 Autoimmune Disease Research Activities
Date:7/27/2011

SAN DIEGO, July 27, 2011 /PRNewswire/ -- Visionary Pharmaceuticals, Inc., announced today that the company has raised seed round investments from a consortium of Angel Investors. The company is using the capital to develop novel small molecule retinoic acid related orphan receptor (ROR) modulators targeting TH17 T-lymphocytes for the treatment of various autoimmune disorders including rheumatoid arthritis, multiple sclerosis, psoriasis and COPD.

Visionary Pharmaceuticals has created BindingSIGHTs, a proprietary computational technology platform which encompasses an advanced suite of structural biology and chemical informatic tools. BindingSIGHTs enables sophisticated virtual screening and structure-based drug design for challenging molecular drug targets. Visionary Pharmaceuticals has also created the MANIFOLD virtual compound library of more than 22 million compounds, which have been screened against ROR BindingSIGHTs fingerprints. High-scoring drug-like hits have been docked to structural models of the ROR ligand binding site to yield focused compound sets. These compounds are synthesized and screened in cell-based assays providing novel highly ligand-efficient chemical matter to drive structure-based drug discovery.

Visionary Pharmaceuticals has created an innovative drug discovery engine utilizing novel proprietary technology to focus on nuclear hormone receptors. Nuclear hormone receptor modulators represent 15% of all drugs approved in the US and account for more than $27 billion in annual sales. "Our BindingSIGHTs technology and MANIFOLD library enables us to save both time and money in generating the best possible lead series. With the initial seed round investments we are now able to launch full-scale research activities in our state-of-the-art labs," said Gordon Alton, Ph.D., President and CEO of Visionary Pharmaceuticals. "We have assembled a veteran leadership team with proven expertise in driving novel therapies to IND. Additionally, our Board of Directors and Scientific Advisory Board bring us a depth of industry experience in successfully driving high quality drug discovery and development programs and delivering high-value exits. Collectively this experience has resulted in more than a dozen novel drugs either marketed or in clinical trials."

About Visionary Pharmaceuticals

Visionary Pharmaceuticals, Inc. is a privately held drug discovery company focused on new small molecule therapies in inflammation and cancer. Visionary Pharmaceuticals' computational BindingSIGHTs technology and MANIFOLD virtual compound library provides advanced structural biology capabilities to optimize the development of drug candidates. Visionary Pharmaceuticals is currently developing retinoic acid related orphan receptor (ROR) modulators targeting TH17 cells in a variety of diseases. To learn more about Visionary Pharmaceuticals, please visit www.visionarypharmaceuticals.com.

CONTACT:  Gordon Alton, +1-858-335-8120, gordon@visionarypharmaceuticals.com


'/>"/>
SOURCE Visionary Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. PreXion, Inc. Names Visionary Industry Leader, Motoaki Saito, M.D., Ph.D. as CEO
2. Life Technologies Announces Visionary Winners of the Ion Torrent PGM Grants Program in Europe
3. Janssen Pharmaceuticals, Inc. Announces Definitive Agreement to Divest Ortho Dermatologics Division
4. Gamma Pharmaceuticals, Inc. Holds Special Shareholders Meeting
5. Sigma-Tau Pharmaceuticals, Inc. Announces Addition of VP of Finance
6. Par Pharmaceutical Companies Announces a Restructuring of Its Branded Division, Strativa Pharmaceuticals, to Maximize Profitability
7. Gamma Pharmaceuticals, Inc. Completes Sale and Books Revenue with National Pharmacy Chain
8. Ampio Pharmaceuticals, Inc. Releases Results From Phase III Clinical Trial of Zertane™ for the Treatment of Premature Ejaculation (PE), the Most Prevalent Form of Male Sexual Dysfunction
9. Pacira Pharmaceuticals, Inc. Announces Inclusion in Russell 3000 Index
10. Drs. Ben Machielse Joins Omthera Pharmaceuticals, Inc. as Chief Operating Officer
11. Vista Partners Initiates Coverage on ADVENTRX Pharmaceuticals, Inc.; Target Price $7.50
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... YORK , March 24, 2017 ... and Equipment stocks, which are: Neovasc Inc. (NASDAQ: NVCN), Hologic ... Heart Inc. (NASDAQ: SSH ). These companies are ... its prior gains on Thursday, March 23 rd , 2017, ... afternoon, while shares of health care companies in the S&P ...
(Date:3/24/2017)... 2017  HealthMine surveys with 9,250 insured consumers fielded ... plan members want help from their plans in five ... their health, 2) help closing gaps in care, 3) ... and 5) relevant, real-time guidance. Meeting these needs is ... A Reason to Stay Engaged ...
(Date:3/24/2017)... The Board of Directors of Nordic Nanovector ASA (OSE: ... complete 2016 Annual Accounts with notes. The report is attached ... the section Investor Relations/Reports and presentations/Annual Reports. ... For further information, please ... Cell: +47-91-51-95-76 Email: ir@nordicnanovector.com Media enquiries: ...
Breaking Medicine Technology:
(Date:3/24/2017)... ... ... “Finding Christ Through Social Media: Year One #A365DayJourney to ... path toward true communion with God. “Finding Christ Through Social Media: Year One ... published author Lea Michelle Johnson, a follower of Christ, wife and mother who ...
(Date:3/24/2017)... ... March 24, 2017 , ... “The Communion of Saints: ... of God in congregations across the United States. “The Communion of Saints” ... 1964 who has served congregations in seven states throughout his long career of ...
(Date:3/23/2017)... ... ... A recent report from the National Council on Teacher Quality (NCTQ) advocates ... based on a review of GPA and SAT/ACT requirements at 221 institutions in 25 ... argues that this higher bar should be set by states, by the Council for ...
(Date:3/23/2017)... Braunfels, TX (PRWEB) , ... March 23, 2017 , ... ... new clinic, located at 960 Gruene Road in Building 2. The clinic is the ... Dr. Andrew Bennett, PT, says opening the company’s second New Braunfels location brings things ...
(Date:3/23/2017)... ... ... The MBI “Hall of Fame” recognizes the contributions of those whose careers are or were ... careers of all others involved. , On Monday, March 21st, 2017 Laurie Robert, ... Fame. The induction took place during the World of Modular – Award Gala in ...
Breaking Medicine News(10 mins):